GASTROESOPHAGEAL ADENOCARCINOMA
Clinical trials for GASTROESOPHAGEAL ADENOCARCINOMA explained in plain language.
Never miss a new study
Get alerted when new GASTROESOPHAGEAL ADENOCARCINOMA trials appear
Sign up with your email to follow new studies for GASTROESOPHAGEAL ADENOCARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Can switching cancer therapy early extend life in stomach cancer?
Disease control Not yet recruitingThis trial is testing whether switching to a different drug combination after initial chemotherapy can help people with advanced gastroesophageal cancer live longer without the disease worsening. Participants first receive standard chemotherapy plus an immunotherapy drug (tisleli…
Matched conditions: GASTROESOPHAGEAL ADENOCARCINOMA
Phase: PHASE3 • Sponsor: Gruppo Oncologico del Nord-Ovest • Aim: Disease control
Last updated Aug 15, 2026 00:00 UTC
-
Could a $4 statin improve cancer survival?
Disease control Not yet recruitingThis phase II trial tests whether adding simvastatin, a widely used cholesterol medication, to standard chemotherapy (with or without immunotherapy) can improve outcomes for people with gastroesophageal adenocarcinoma. About 184 patients will be randomly assigned to receive eithe…
Matched conditions: GASTROESOPHAGEAL ADENOCARCINOMA
Phase: PHASE2 • Sponsor: McGill University Health Centre/Research Institute of the McGill University Health Centre • Aim: Disease control
Last updated Jul 12, 2026 00:00 UTC
-
New cancer drug HH160 enters first human tests for advanced tumors
Disease control Not yet recruitingThis early-stage study tests a new drug called HH160 in about 56 adults with advanced solid tumors (cancers that have spread). The main goals are to check safety, find the best dose, and see if the drug shrinks tumors. Participants will receive HH160 alone or with other cancer tr…
Matched conditions: GASTROESOPHAGEAL ADENOCARCINOMA
Phase: PHASE1 • Sponsor: Huahui Health • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
New combo therapy aims to wipe out stomach cancer before surgery
Disease control Not yet recruitingThis phase 2 trial tests two different drug combinations given before surgery for people with a specific type of stomach cancer (dMMR/MSI-H). Participants will receive the immunotherapy drug adebrelimab plus either chemotherapy or another immunotherapy drug (SHR-8068). The goal i…
Matched conditions: GASTROESOPHAGEAL ADENOCARCINOMA
Phase: PHASE2 • Sponsor: Shanghai Zhongshan Hospital • Aim: Disease control
Last updated Jun 27, 2026 09:00 UTC